Shanghai, China

Shilan Liu

This inventor holds 13 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Kpc Pharmaceuticals, Inc.. Active years: 2016-2022.

USPTO Granted Patents = 13 

% Patents Active = 92.3

 

 

Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Nanjing, CN (2019)
  • Shanghai, CN (2016 - 2022)

Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: The Innovative Journey of Shilan Liu

Introduction: Shilan Liu, a pioneering inventor hailing from Shanghai, China, has made significant contributions to the world of technology and innovation through his groundbreaking inventions and patents.

Latest Patents: Shilan Liu's latest patents include cutting-edge technologies in the fields of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a career spanning over two decades, Shilan Liu has established himself as a leading figure in the global innovation landscape. His work has not only revolutionized existing industries but has also paved the way for new technological advancements.

Collaborations: Throughout his career, Shilan Liu has collaborated with top research institutions, universities, and multinational companies to bring his inventions to life. His ability to work across disciplines and borders has led to the development of groundbreaking technologies with far-reaching impacts.

Conclusion: Shilan Liu's passion for innovation, coupled with his relentless drive to push the boundaries of what is possible, has solidified his position as a trailblazer in the world of inventions. His continued dedication to creating solutions for the challenges of tomorrow ensures that his legacy will endure for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…